Evidence map›Paper›PMID 36823287›Full record

ReviewNPJ vaccines2023

Independent control of COVID-19 vaccines by EU Official Control Authority Batch Release: challenges, strengths and successes.

Catherine Milne, Ralf Wagner, François Cano, Martijn Bruysters, Geneviève Waeterloos, Dieter Pullirsch, Michael Wierer, Laurent Mallet

Open access · goldAbstract readReview
In one paragraph

Review in NPJ vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 5 countries.

Catherine MilneEuropean Directorate for the Quality of Medicines & HealthCare, Department of Biological Standardisation, OMCL Network and HealthCare, Council of Europe, Strasbourg, France. catherine.milne@edqm.eu.
Ralf WagnerPaul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen, Germany.
François CanoFrench National Agency for Medicines and Health Product Safety (ANSM), Laboratory Controls Division, Lyon, France.ORCID http://orcid.org/0000-0001-7953-6892
Martijn BruystersDutch National Institute for Public Health and Environment, Centre for Health Protection (GZB), Bilthoven, The Netherlands.ORCID http://orcid.org/0000-0002-1061-1038
Geneviève WaeterloosSciensano, Scientific Directorate Biological Health Risks, Service quality of vaccines and blood products, Brussels, Belgium.
Dieter PullirschAustrian Federal Office for Safety in Health Care, Austrian Agency for Health and Food Safety, Vienna, Austria.
Michael WiererEuropean Directorate for the Quality of Medicines & HealthCare, Department of Biological Standardisation, OMCL Network and HealthCare, Council of Europe, Strasbourg, France.
Laurent MalletEuropean Directorate for the Quality of Medicines & HealthCare, Department of Biological Standardisation, OMCL Network and HealthCare, Council of Europe, Strasbourg, France.
Conseil de L'EuropeAgence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail · FRAustrian Agency for Health and Food Safety · ATDirectorate-General for Health and Food Safety · BEEuropean Council · BENational Institute for Public Health and the Environment · NLPaul Ehrlich Institut · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vaccines have been a key tool in stemming the tide of the COVID-19 pandemic. The rapid development of effective vaccines against COVID-19, together with their regulatory approval and wide scale distribution has been achieved in an impressively short period thanks to the intense efforts of many. In parallel to vaccine development, the EU considered it important to prepare for the independent control of the COVID-19 vaccines, including testing, to help ensure that only vaccines that comply with the approved quality requirements reach the public and to help improve/increase public confidence in the vaccines. The existing EU Official Control Authority Batch Release (OCABR) system, co-ordinated by the European Directorate for the Quality of Medicines and HealthCare (EDQM), was able to effectively respond to the need, through rapid co-ordination, work-sharing, advance planning and early interaction with manufacturers, the Coalition for Epidemic Preparedness Innovation (CEPI) and regulatory authorities. The Official Medicines Control Laboratories (OMCLs) involved in the OCABR activity, using the strength of the established system in the OCABR network and adaptations to the crisis conditions, were ready to release the first COVID-19 vaccine batches, after protocol review and testing, at the time of the conditional marketing authorisation for each of the COVID-19 vaccines, with no delay for batches reaching the public. Thanks to the dedication of resources by the EU and national authorities as well as by the EDQM, this was done without impacting the release of the other vaccines and human blood and plasma derived medicinal products, essential for public health. Transparency and communication of practices were important factors to support reliance on the OCABR outcome in non-EU countries, with the goal to improve access to vaccines in Europe and beyond. An overview of the process, legal background, challenges and successes of OCABR for COVID-19 vaccines as well as a look at the international perspective and lessons learned is provided.

Identifiers

PMID36823287
PMCPMC9950138
OpenAlexW4321617075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.